X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
USA (Orange Book)
Europe
0
Canada
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
https://www.globenewswire.com//news-release/2023/10/24/2765435/0/en/LianBio-Enters-into-Agreement-with-Bristol-Myers-Squibb-for-Mavacamten-in-China-and-Other-Asian-Markets.html
https://www.globenewswire.com/news-release/2023/08/28/2732918/0/en/LianBio-Announces-Results-from-Phase-3-EXPLORER-CN-Trial-of-Mavacamten-Presented-at-the-European-Society-of-Cardiology-Congress-and-Simultaneous-Publication-in-JAMA-Cardiology.html
https://www.ema.europa.eu/en/documents/overview/camzyos-epar-medicine-overview_en.pdf
https://www.ema.europa.eu/en/documents/overview/camzyos-epar-medicine-overview_en.pdf
https://finance.yahoo.com/news/bristol-myers-squibb-receives-european-200100151.html#:~:text=PRINCETON%2C%20N.J.%2C%20June%2026%2C,class%20II%2DIII)%20obstructive%20hypertrophic
https://www.fiercepharma.com/pharma/carrying-blockbuster-sales-expectations-bristols-camyzos-picks-early-nod-englands-nice
https://www.globenewswire.com/news-release/2023/05/11/2666545/0/en/LianBio-Announces-Marketing-Approval-of-CAMZYOS-mavacamten-in-the-Macau-Special-Administrative-Region-SAR-of-China.html
https://www.globenewswire.com/news-release/2023/04/21/2651891/0/en/LianBio-Announces-China-National-Medical-Products-Administration-NMPA-Acceptance-with-Priority-Review-of-New-Drug-Application-for-Mavacamten-for-the-Treatment-of-Patients-with-Obst.html
https://endpts.com/bristol-myers-lines-up-a-date-with-the-fda-to-expand-the-footprint-of-its-13b-heart-drug/
https://www.globenewswire.com/news-release/2022/08/10/2495701/0/en/LianBio-Completes-Enrollment-in-Pivotal-Phase-3-EXPLORER-CN-Trial-of-Mavacamten-in-Chinese-Obstructive-Hypertrophic-Cardiomyopathy-Patients.html
https://www.biopharmadive.com/news/bristol-myers-fda-approval-heart-drug-camzyos-myokardia/622732/
https://www.globenewswire.com/news-release/2022/04/29/2432546/0/en/U-S-Food-and-Drug-Administration-Approves-Camzyos-mavacamten-for-the-Treatment-of-Adults-with-Symptomatic-New-York-Heart-Association-Class-II-III-Obstructive-Hypertrophic-Cardiomyo.html
https://endpts.com/bristol-myers-touts-upbeat-data-for-its-blockbuster-heart-drug-candidate/
https://endpts.com/with-delayed-review-date-looming-bristol-myers-uncorks-more-winning-data-for-blockbuster-potential-heart-drug/
https://www.globenewswire.com/news-release/2022/02/15/2385081/0/en/LianBio-Announces-Mavacamten-Granted-Breakthrough-Therapy-Designation-in-China.html
https://www.globenewswire.com/news-release/2022/01/10/2363809/0/en/LianBio-Announces-First-Patient-Dosed-in-Registrational-Phase-3-EXPLORER-CN-Trial-of-Mavacamten-in-Chinese-Patients-with-Obstructive-Hypertrophic-Cardiomyopathy.html
https://endpts.com/fda-delays-its-decision-on-bristol-myers-13b-heart-drug-another-three-months/
https://www.fiercepharma.com/marketing/utah-jazz-rookie-opens-up-about-heart-diagnosis-bms-awareness-campaign
https://endpts.com/a-couple-months-ahead-of-its-pdufa-data-bristol-myers-rolls-out-long-term-data-for-mavacamten/
https://www.fiercebiotech.com/biotech/bristol-myers-13b-myokardia-heart-drug-gets-along-beta-blockers-as-clock-ticks-down-to-fda
https://icer.org/news-insights/press-releases/icer-publishes-evidence-report-on-mavacamten-for-hypertrophic-cardiomyopathy/
https://www.biospace.com/article/releases/european-medicines-agency-validates-bristol-myers-squibb-s-application-for-mavacamten-for-the-treatment-of-obstructive-hypertrophic-cardiomyopathy/?s=71
https://www.prweb.com/releases/explorer_hcm_trial_finds_substantial_health_status_improvements_with_mavacamten_in_patients_with_symptomatic_obstructive_hypertrophic_cardiomyopathy_ohcm/prweb17947731.htm
https://www.globenewswire.com/news-release/2020/05/11/2030998/0/en/MyoKardia-Announces-Primary-and-All-Secondary-Endpoints-Met-in-Phase-3-EXPLORER-Clinical-Trial-of-Mavacamten-for-the-Treatment-of-Obstructive-Hypertrophic-Cardiomyopathy.html
https://myokardia.gcs-web.com/news-releases/news-release-details/data-maverick-hcm-study-mavacamten-non-obstructive-hypertrophic
https://endpts.com/sanofi-walks-away-from-myokardia-heart-drug-partnership-long-before-key-data-readout/
Market Place
Share 
